ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABVC ABVC BioPharma, Inc.

Closed 10-23 16:00:00 EDT

1.04

-0.01

-0.70%

盘后1.04

+0.00+0.22%

19:30 EDT

High1.06	Low1.03	Vol22.01K
Open1.04	D1 Closing1.05	Amplitude2.86%
Mkt Cap27.72M	Tradable Cap22.70M	Total Shares26.65M
T/O22.99K	T/O Rate0.10%	Tradable Shares21.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABVC","market":"US","secType":"STK","nameCN":"ABVC BioPharma, Inc.","latestPrice":1.04,"timestamp":1792785600000,"preClose":1.0473,"halted":0,"volume":22011,"hourTrading":{"tag":"盘后","latestPrice":1.0423,"preClose":1.04,"latestTime":"19:30 EDT","volume":8011,"amount":8337.5023,"timestamp":1792798203792,"change":0.0023,"changeRate":0.002212,"amplitude":0.002981},"delay":0,"changeRate":-0.00697030459276221,"floatShares":21826200,"shares":26654365,"eps":-0.285468,"marketStatus":"Closed","change":-0.0073,"latestTime":"10-23 16:00:00 EDT","open":1.04,"high":1.06,"low":1.03,"amount":22992.0456777,"amplitude":0.028645,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.285468,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":5,"adr":0,"listingDate":1627963200000,"exchange":"NASDAQ","adjPreClose":1.0473,"postHourTrading":{"tag":"盘后","latestPrice":1.0423,"preClose":1.04,"latestTime":"19:30 EDT","volume":8011,"amount":8337.5023,"timestamp":1792798203792,"change":0.0023,"changeRate":0.002212,"amplitude":0.002981},"volumeRatio":0.675429,"impliedVol":0.4964,"impliedVolPercentile":0.2829},"requestUrl":"/m/hq/s/ABVC/tweets","defaultTab":"tweets","newsList":[{"id":"2677671330","title":"Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2677671330","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677671330?lang=en_us&edition=fundamental","pubTime":"2026-10-21 20:30","pubTimestamp":1792585800,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Oct.  21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar TMS technology with direct patient care through ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/21/3385514/0/en/neuronetics-to-report-third-quarter-2026-financial-and-operating-results-and-host-conference-call.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TMS","BK4082","BK4176","ABVC","STIM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677676760","title":"Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2677676760","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677676760?lang=en_us&edition=fundamental","pubTime":"2026-10-21 20:00","pubTimestamp":1792584000,"startTime":"0","endTime":"0","summary":"Seven presentations include pediatric Phase 4 studies of AZSTARYS (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM (Delayed-Release/Extended-Release Methylphenidate)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/21/3385443/34897/en/collegium-to-present-pediatric-and-real-world-research-across-adhd-portfolio-at-aacap-and-nei-fall-congresses.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4135","BK4588","ADHD","POW","BK4096","RSHO","CNS","ABVC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675452713","title":"Seaport Therapeutics initiated with a Buy at Canaccord on MDD potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2675452713","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675452713?lang=en_us&edition=fundamental","pubTime":"2026-10-14 18:50","pubTimestamp":1791975056,"startTime":"0","endTime":"0","summary":"As previously reported, Canaccord analyst Sumant Kulkarni initiated coverage of Seaport Therapeutics (SPTX) with a Buy rating and $28 price target ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/seaport-therapeutics-initiated-with-a-buy-at-canaccord-on-mdd-potential-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/seaport-therapeutics-initiated-with-a-buy-at-canaccord-on-mdd-potential-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPTX","BK4007","ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674866345","title":"Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2674866345","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674866345?lang=en_us&edition=fundamental","pubTime":"2026-10-10 01:32","pubTimestamp":1791567135,"startTime":"0","endTime":"0","summary":"Collegium Pharmaceutical (COLL) should benefit from continued strength in its attention-deficit/hyperactivity disorder drugs, limited near-term generic risk for Belbuca and stable pricing trends, whil","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1983299246.USD","BK4139","ABVC","BK4557","BK4007","COLL","BK4584","LU2324357040.USD","TEVA","BK4585","BK4596","BK4559","BK4566","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011796","title":"Alkermes Advances Adult ADHD Pipeline With New Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011796","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011796?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:30","pubTimestamp":1791390650,"startTime":"0","endTime":"0","summary":"Alkermes plc ($ALKS) announced an update on their ongoing clinical study. Alkermes plc (ALKS) is running a mid-stage clinical study to test a new A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alkermes-advances-adult-adhd-pipeline-with-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alkermes-advances-adult-adhd-pipeline-with-new-phase-2-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","ABVC","ALKS","PSIL","BK4139","MEDX","FBT","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673205650","title":"Collegium Launches \"Start Talking ADHD\" with Practical Support to Help Families Navigate Care, School and Everyday Life","url":"https://stock-news.laohu8.com/highlight/detail?id=2673205650","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673205650?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288000,"startTime":"0","endTime":"0","summary":"New resource hub builds on Collegium’s growing ADHD portfolio and commitment to supporting people and families beyond the clinical settingSTOUGHTON, Mass., Oct.  06, 2026 (GLOBE NEWSWIRE) -- Collegium","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/06/3375438/34897/en/collegium-launches-start-talking-adhd-with-practical-support-to-help-families-navigate-care-school-and-everyday-life.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4590","BK4206","IEP","ADHD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669745486","title":"Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2669745486","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669745486?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:00","pubTimestamp":1790168400,"startTime":"0","endTime":"0","summary":"One cGMP batch, manufactured in-house under Optimi's Health Canada Drug Establishment Licence, supplies both the Canadian trial and Australian clinicsVANCOUVER, British Columbia, Sept.  23, 2026 (GLOB","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/23/3367523/0/en/optimi-health-completes-psilocybin-production-for-health-canada-approved-phase-2-mdd-trial-and-commercial-trd-supply.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","OPTH","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669412748","title":"Aytu Fiscal Q4 2026 Earnings: EXXUA Drives Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2669412748","media":"TradingKey","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669412748?lang=en_us&edition=fundamental","pubTime":"2026-09-23 05:08","pubTimestamp":1790111297,"startTime":"0","endTime":"0","summary":"Aytu BioPharma’s fiscal Q4 2026 net revenue rose 6.4% to $16.1 million, while diluted net loss per share improved to $0.00 from $2.92 a year earlier. EXXUA generated $3.9 million in its first full launch quarter and helped offset declines in the ADHD and Pediatric portfolios. Gross margin narrowed to 64.6% from 67.8%, and adjusted EBITDA fell to $0.5 million from $2.0 million as commercialization spending increased. The company ended June 30, 2026 with $26.3 million in cash, down from $31.0 million a year earlier.","market":"fut","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock1.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock1.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262181336-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AYTU","BK4007","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669232251","title":"Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2669232251","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669232251?lang=en_us&edition=fundamental","pubTime":"2026-09-22 23:39","pubTimestamp":1790091552,"startTime":"0","endTime":"0","summary":"Alkermes (ALKS) recent attention-deficit/hyperactivity disorder data increased its management's confidence in ALKS7290 and reinforced the potential of its broader \"orexin pipeline,\" RBC Capital Market","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ALKS","FBT","PSCH","IBRN","ABVC","MEDX","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669167844","title":"Alkermes data show measurable improvements in ADHD, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2669167844","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669167844?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:40","pubTimestamp":1790008814,"startTime":"0","endTime":"0","summary":"H.C. Wainwright keeps a Neutral rating on Alkermes (ALKS) after the company reported the first clinical evidence of an orexin-2 receptor agonist pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-data-show-measurable-improvements-in-adhd-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-data-show-measurable-improvements-in-adhd-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","ABVC","BK4139","PSCH","ALKS","FBT","PSIL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169069","title":"Alkermes: Orexin Agonism in ADHD Shows Early Promise; Buy Rating Reiterated with Unchanged $62 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169069","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669169069?lang=en_us&edition=fundamental","pubTime":"2026-09-21 22:15","pubTimestamp":1790000126,"startTime":"0","endTime":"0","summary":"Ami Fadia, an analyst from Needham, reiterated the Buy rating on Alkermes. The associated price target remains the same with $62.00. Ami Fadia has ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alkermes-orexin-agonism-in-adhd-shows-early-promise-buy-rating-reiterated-with-unchanged-62-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alkermes-orexin-agonism-in-adhd-shows-early-promise-buy-rating-reiterated-with-unchanged-62-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669976165","title":"Alkermes Says ADHD Drug Candidate Showed Meaningful Improvements in Phase 1b Study; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2669976165","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669976165?lang=en_us&edition=fundamental","pubTime":"2026-09-21 20:43","pubTimestamp":1789994623,"startTime":"0","endTime":"0","summary":"Alkermes  said Monday its drug candidate ALKS 7290 showed clinically meaningful improvements from baseline on exploratory endpoints in a phase 1b study in patients with attention-deficit hyperactivity disorder or ADHD.The company said it measured improvements using the Adult ADHD Investigator Symptom Rating Scale and Clinical Global Impression-Severity Scale after 14 days of treatment.ALKS 7290 was generally well-tolerated at all doses tested in healthy volunteers and adults with ADHD, the company said. The study enrolled 50 adults with ADHD in a double-blind, placebo-controlled, parallel-group trial with two cohorts, it added.The company said it enrolled the first of an expected 312 participants in a phase-2 study this month. The trial will evaluate the safety and efficacy of once-daily and split doses of ALKS 7290 compared to placebo, with data expected next year.Shares of the company were up over 7% in Monday's premarket activity.Price: 46.50, Change: +3.11, Percent Change: +7.17","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALKS","ABVC","IBRN","MEDX","FBT","PSIL","BK4139","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669163577","title":"Alkermes jumps 8% to $46.99 after Phase I adult ADHD data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669163577","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669163577?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:50","pubTimestamp":1789991414,"startTime":"0","endTime":"0","summary":"07:46 EDT Alkermes (ALKS) jumps 8% to $46.99 after Phase I adult ADHD data Published first on TheFly – the ultimate source for real-time, market-mo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-jumps-8-to-46-99-after-phase-i-adult-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-jumps-8-to-46-99-after-phase-i-adult-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","MEDX","ALKS","PSCH","FBT","IBRN","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669684191","title":"Helus Pharma presents new analyses on HLP003 in MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2669684191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669684191?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:35","pubTimestamp":1789990521,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) announced the presentation of four posters evaluating HLP003 at Psych Congress 2026, September 15-19, 2026, at the Ernest Moria...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-pharma-presents-new-analyses-on-hlp003-in-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-pharma-presents-new-analyses-on-hlp003-in-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","HELP","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669916887","title":"Alkermes announces Phase 1b results of ALKS 7290 in ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2669916887","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669916887?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:05","pubTimestamp":1789988737,"startTime":"0","endTime":"0","summary":"Alkermes (ALKS) announced topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-announces-phase-1b-results-of-alks-7290-in-adhd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-announces-phase-1b-results-of-alks-7290-in-adhd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSCH","MEDX","IBRN","PSIL","ALKS","FBT","BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667991516","title":"Analyst Reaffirms Buy on Contineum, Highlighting PIPE-791 IPF Upside Despite Muscarinic MDD Trial Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2667991516","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667991516?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:25","pubTimestamp":1789424719,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has reiterated their bullish stance on CTNM stock, giving a Buy rating on September 3. Myles Minter has given hi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reaffirms-buy-on-contineum-highlighting-pipe-791-ipf-upside-despite-muscarinic-mdd-trial-setback-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reaffirms-buy-on-contineum-highlighting-pipe-791-ipf-upside-despite-muscarinic-mdd-trial-setback-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CTNM","ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666910405","title":"Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2666910405","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666910405?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:25","pubTimestamp":1789050337,"startTime":"0","endTime":"0","summary":"Optimi Health (OPTH) announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with maj...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/optimi-health-to-initiate-phase-2-trial-of-psilocybin-assisted-therapy-for-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","BBC","BK4139","HYLG","BK4007","IDNA","OPTH","MEDX","PSIL","ABVC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372197","title":"Analyst Reiterates Buy on Definium Therapeutics, Maintains $75 Price Target Following De-Risking of DT120 ODT in MDD and GAD","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372197","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372197?lang=en_us&edition=fundamental","pubTime":"2026-09-09 03:25","pubTimestamp":1788895521,"startTime":"0","endTime":"0","summary":"Analyst Francois Brisebois of LifeSci Capital reiterated a Buy rating on Definium Therapeutics, retaining the price target of $75.00. Francois Bris...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-definium-therapeutics-maintains-75-price-target-following-de-risking-of-dt120-odt-in-mdd-and-gad-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-definium-therapeutics-maintains-75-price-target-following-de-risking-of-dt120-odt-in-mdd-and-gad-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","ODT","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665735956","title":"Mizuho survey shows no consensus into Alkermes ADHD data","url":"https://stock-news.laohu8.com/highlight/detail?id=2665735956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665735956?lang=en_us&edition=fundamental","pubTime":"2026-09-05 03:35","pubTimestamp":1788550508,"startTime":"0","endTime":"0","summary":"Mizuho conducted a survey of 13 investors ahead of Alkermes (ALKS)’ Phase 1b trial of ALKS-7290 in adult attention-deficit/hyperactivity disorder, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","ADHD","PSIL","BK4139","IBRN","ABVC","ALKS","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664637869","title":"Supernus Pharmaceuticals (SUPN) On Chloe Kim ADHD Push And Whether Undervalued Looks Priced In","url":"https://stock-news.laohu8.com/highlight/detail?id=2664637869","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664637869?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:23","pubTimestamp":1788294236,"startTime":"0","endTime":"0","summary":"Olympic snowboarder Chloe Kim’s new awareness partnership with Supernus Pharmaceuticals (SUPN) puts extra focus on Qelbree and adult ADHD and may lead some investors to recheck how the stock’s current pricing reflects its ADHD portfolio.\nSupernus Pharmaceuticals’ stock is trading at US$44.21, with the 1-day share price return of 1.10% partially offsetting a weaker year to date share price return that is down 10.63%. The 5-year total shareholder return of 61% points to a much stronger longer...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/supernus-pharmaceuticals-supn-on-chloe-kim-adhd-push-and-whe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-supn/supernus-pharmaceuticals/news/supernus-pharmaceuticals-supn-on-chloe-kim-adhd-push-and-whe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ABVC","SUPN","BK4007","ADHD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abvcpharma.com","stockEarnings":[{"period":"1week","weight":0.1231},{"period":"1month","weight":-0.0972},{"period":"3month","weight":-0.0893},{"period":"6month","weight":-0.0212},{"period":"1year","weight":-0.6286},{"period":"ytd","weight":-0.5083}],"compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.0122},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.0701},{"period":"1year","weight":0.144},{"period":"ytd","weight":0.1203}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.072395},{"month":2,"riseRate":0.125,"avgChangeRate":-0.057705},{"month":3,"riseRate":0.625,"avgChangeRate":0.040736},{"month":4,"riseRate":0.375,"avgChangeRate":0.01167},{"month":5,"riseRate":0.5,"avgChangeRate":0.035623},{"month":6,"riseRate":0.375,"avgChangeRate":1.167092},{"month":7,"riseRate":0.375,"avgChangeRate":-0.130229},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.065211},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.032147},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.060927},{"month":11,"riseRate":0.625,"avgChangeRate":0.051458},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012195}],"exchange":"NASDAQ","name":"ABVC BioPharma, Inc.","nameEN":"ABVC BioPharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ABVC BioPharma, Inc.,ABVC,ABVC BioPharma, Inc.股票,ABVC BioPharma, Inc.股票老虎,ABVC BioPharma, Inc.股票老虎国际,ABVC BioPharma, Inc.行情,ABVC BioPharma, Inc.股票行情,ABVC BioPharma, Inc.股价,ABVC BioPharma, Inc.股市,ABVC BioPharma, Inc.股票价格,ABVC BioPharma, Inc.股票交易,ABVC BioPharma, Inc.股票购买,ABVC BioPharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction